Artiva Biotherapeutics Prices $300 Mln Stock, Pre-Funded Warrants Offering; Shares Rise

(RTTNews) - Artiva Biotherapeutics, Inc. (ARTV), a clinical-stage biotechnology company, on Friday announced the pricing of an underwritten offering of stock and pre-funded warrants.

The offering consists of 23.87 million shares of stock priced at $11.52 per share and pre-funded warrants to purchase 2.17 million shares at a purchase price of $11.5199 per warrant.

The transaction is expected to close on or about May 11.

The offering is expected to raise approximately $300 million in gross proceeds.

In the pre-market trading, Artiva Biotherapeutics is 17.41% higher at $14.65 on the Nasdaq.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This data feed is not available at this time.